Invited Talk: VM202, a DNA-based Potential Disease-Modifying Treatment for Painful Diabetic Neuropathy and Foot Ulcer

VM202 is a DNA-based medicine designed to simultaneously express two isoforms of protein called hepatocyte growth factor (HGF). HGF is well known to induce the formation of new blood vessels and the growth and regeneration of nerve cells. Currently, VM202 is being tested for 4 major cardiovascular or neurological diseases. In all cases, VM202 is delivered by a simple intramuscular injection around the affected area. A phase III study for chronic, non-healing foot ulcer associated with diabetes (VM202-PAD) has been approved by the US FDA and initiated patient enrollment in 2017 in the US. A phase III study for painful diabetic peripheral neuropathy (VM202-DPN) was successfully initiated in the US in 2016, and more than 300 patients have been treated. Following the success of phase I trial for coronary artery disease (VM202-CAD), a phase II study is underway in Korea. VM202 also successfully completed a phase I/II trial for amyotrophic lateral sclerosis (VM202-ALS). In this presentation, the clinical development results of VM202 will be shared.